Lynparza OK'd as First-Line Maintenance of BRCA-Mutated Advanced Ovarian CA

Lynparza, a poly (ADP-ribose) polymerase (PARP) inhibitor is already approved to treat certain breast, epithelial ovarian, fallopian tube or primary peritoneal cancers based on an FDA-approved companion diagnostic.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2RmZxum